You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
东曜(01875.HK)续涨23%曾创五个月高 核心在研新药TAB008 III期达临床试验终点
阿思达克 04-22 11:11
东曜药业(01875.HK)核心在研新药TAB008 III期达临床试验预设主要终点,该股连升第五天,今早曾逆市飙升55%高见6.2元,创五个月高遇压,现造4.95元,续涨近23%,一向薄弱成交增至125万股。

东曜是内地一间临床阶段仍未有盈利的生物制药公司,股份去年11月8日以每股6.55元来港上市,挂牌後股价一直「潜水」,首挂日高见6.43元已行人止步。

东曜昨天收市後公布,旗下核心在研产品TAB008的随机III期临床试验最近达到预设主要终点(即是比较TAB008和阿瓦斯汀疗效),集团将继续如期推进TAB008新药申请。TAB008是一种抗血管内皮细胞生长因子单克隆抗体在研药物,是目前集团进度最快在研生物药。另外,该公司昨天(21日)起正式委任刘军为公司首席运营官,将负责集团运营管理,并协助总经理共同推进海外业务发展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account